Avacta Group Plc (LON:AVCT - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 43.97 ($0.58) and traded as low as GBX 32.50 ($0.43). Avacta Group shares last traded at GBX 32.75 ($0.43), with a volume of 1,419,363 shares.
Avacta Group Price Performance
The stock has a market capitalization of £132.97 million, a price-to-earnings ratio of -4.50 and a beta of 1.12. The company has a quick ratio of 4.96, a current ratio of 1.29 and a debt-to-equity ratio of 52.53. The stock has a fifty day moving average of GBX 36.47 and a 200-day moving average of GBX 43.55.
Avacta Group Company Profile
(
Get Free Report)
Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.
Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).
Featured Articles
Before you consider Avacta Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avacta Group wasn't on the list.
While Avacta Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
